Simultaneous determination of six tyrosine kinase inhibitors in human plasma using HPLC-Q-Orbitrap mass spectrometry
Gefitinib, erlotinib, icotinib, crizotinib, lapatinib and apatinib are targeted cancer therapy agents acting through inhibition of tyrosine kinase. Method for quantifying these six drugs in human plasma of patients was required. An HPLC-Q-Orbitrap method (based on HPLC-MS/MS) was developed and valid...
Gespeichert in:
| Veröffentlicht in: | Bioanalysis 2017-06, Vol.9 (12), p.925-935 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 935 |
|---|---|
| container_issue | 12 |
| container_start_page | 925 |
| container_title | Bioanalysis |
| container_volume | 9 |
| creator | Ni, Mao-Wei Zhou, Jie Li, Hui Chen, Wei Mou, Han-Zhou Zheng, Zhi-Guo |
| description | Gefitinib, erlotinib, icotinib, crizotinib, lapatinib and apatinib are targeted cancer therapy agents acting through inhibition of tyrosine kinase. Method for quantifying these six drugs in human plasma of patients was required.
An HPLC-Q-Orbitrap method (based on HPLC-MS/MS) was developed and validated for the simultaneous detection and quantitation of six tyrosine kinase inhibitors in human plasma. Sample was extracted by liquid-liquid extraction (ethyl acetate: tert-Butyl methyl ether, 1:1 v/v). The method shows a high level of accuracy and reproducibility. The lower limit of quantification was 0.02 ng/ml for apatinib, 0.1 ng/ml for crizotinib, 2.0 ng/ml for lapatinib and 0.05 ng/ml for erlotinib, gefitinib and icotinib. This method was successfully used for apatinib monitoring in plasma of patients with NSCLC.
This simple and reproducible method has potential for monitoring of tyrosine kinase inhibitors in patients' plasma. |
| doi_str_mv | 10.4155/bio-2017-0031 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_4155_bio_2017_0031</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>28617069</sourcerecordid><originalsourceid>FETCH-LOGICAL-c343t-37f6018884643457a3b8d6d6f34d7c37ec759d04f5b3b6c3fe4a48d59df657113</originalsourceid><addsrcrecordid>eNp1kEFPwyAUx4nRuGXu6NXwBVAYFOjRLOpMlkyjnhtKwaGjbYAm7tuPpbqbXN7j8Xv_hB8A1wTfMlIUd7Xr0AITgTCm5AxMiSgE4qQsz0-9xBMwj_EL50MXsmTlJZgsJCcC83IK0pvzwy6p1nRDhI1JJnjXquS6FnYWRvcD0z500bUGfueHaKBrt652qQsxt3A7eNXCfqeiV3DI3CdcvayX6BVtQqaC6qFXMcLYG51C500K-ytwYdUumvlvnYGPx4f35QqtN0_Py_s10pTRhKiwHBMpJeOMskIoWsuGN9xS1ghNhdGiKBvMbFHTmmtqDVNMNnlmeSEIoTOAxlydfxCDsVUfnFdhXxFcHQVWWWB1FFgdBWb-ZuT7ofamOdF_ujJQjoAd0hBM1M602lTjLW84nT39E34A_MOBbQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Simultaneous determination of six tyrosine kinase inhibitors in human plasma using HPLC-Q-Orbitrap mass spectrometry</title><source>MEDLINE</source><source>PubMed Central</source><creator>Ni, Mao-Wei ; Zhou, Jie ; Li, Hui ; Chen, Wei ; Mou, Han-Zhou ; Zheng, Zhi-Guo</creator><creatorcontrib>Ni, Mao-Wei ; Zhou, Jie ; Li, Hui ; Chen, Wei ; Mou, Han-Zhou ; Zheng, Zhi-Guo</creatorcontrib><description>Gefitinib, erlotinib, icotinib, crizotinib, lapatinib and apatinib are targeted cancer therapy agents acting through inhibition of tyrosine kinase. Method for quantifying these six drugs in human plasma of patients was required.
An HPLC-Q-Orbitrap method (based on HPLC-MS/MS) was developed and validated for the simultaneous detection and quantitation of six tyrosine kinase inhibitors in human plasma. Sample was extracted by liquid-liquid extraction (ethyl acetate: tert-Butyl methyl ether, 1:1 v/v). The method shows a high level of accuracy and reproducibility. The lower limit of quantification was 0.02 ng/ml for apatinib, 0.1 ng/ml for crizotinib, 2.0 ng/ml for lapatinib and 0.05 ng/ml for erlotinib, gefitinib and icotinib. This method was successfully used for apatinib monitoring in plasma of patients with NSCLC.
This simple and reproducible method has potential for monitoring of tyrosine kinase inhibitors in patients' plasma.</description><identifier>ISSN: 1757-6180</identifier><identifier>EISSN: 1757-6199</identifier><identifier>DOI: 10.4155/bio-2017-0031</identifier><identifier>PMID: 28617069</identifier><language>eng</language><publisher>England: Future Science Ltd</publisher><subject>Blood Chemical Analysis - methods ; Chromatography, High Pressure Liquid - methods ; Humans ; Limit of Detection ; Linear Models ; method development ; Protein Kinase Inhibitors - blood ; Protein Kinase Inhibitors - pharmacology ; Protein-Tyrosine Kinases - antagonists & inhibitors ; Q-Orbitrap ; Tandem Mass Spectrometry - methods ; therapeutic drug monitoring ; Time Factors</subject><ispartof>Bioanalysis, 2017-06, Vol.9 (12), p.925-935</ispartof><rights>Future Science Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c343t-37f6018884643457a3b8d6d6f34d7c37ec759d04f5b3b6c3fe4a48d59df657113</citedby><cites>FETCH-LOGICAL-c343t-37f6018884643457a3b8d6d6f34d7c37ec759d04f5b3b6c3fe4a48d59df657113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28617069$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ni, Mao-Wei</creatorcontrib><creatorcontrib>Zhou, Jie</creatorcontrib><creatorcontrib>Li, Hui</creatorcontrib><creatorcontrib>Chen, Wei</creatorcontrib><creatorcontrib>Mou, Han-Zhou</creatorcontrib><creatorcontrib>Zheng, Zhi-Guo</creatorcontrib><title>Simultaneous determination of six tyrosine kinase inhibitors in human plasma using HPLC-Q-Orbitrap mass spectrometry</title><title>Bioanalysis</title><addtitle>Bioanalysis</addtitle><description>Gefitinib, erlotinib, icotinib, crizotinib, lapatinib and apatinib are targeted cancer therapy agents acting through inhibition of tyrosine kinase. Method for quantifying these six drugs in human plasma of patients was required.
An HPLC-Q-Orbitrap method (based on HPLC-MS/MS) was developed and validated for the simultaneous detection and quantitation of six tyrosine kinase inhibitors in human plasma. Sample was extracted by liquid-liquid extraction (ethyl acetate: tert-Butyl methyl ether, 1:1 v/v). The method shows a high level of accuracy and reproducibility. The lower limit of quantification was 0.02 ng/ml for apatinib, 0.1 ng/ml for crizotinib, 2.0 ng/ml for lapatinib and 0.05 ng/ml for erlotinib, gefitinib and icotinib. This method was successfully used for apatinib monitoring in plasma of patients with NSCLC.
This simple and reproducible method has potential for monitoring of tyrosine kinase inhibitors in patients' plasma.</description><subject>Blood Chemical Analysis - methods</subject><subject>Chromatography, High Pressure Liquid - methods</subject><subject>Humans</subject><subject>Limit of Detection</subject><subject>Linear Models</subject><subject>method development</subject><subject>Protein Kinase Inhibitors - blood</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Protein-Tyrosine Kinases - antagonists & inhibitors</subject><subject>Q-Orbitrap</subject><subject>Tandem Mass Spectrometry - methods</subject><subject>therapeutic drug monitoring</subject><subject>Time Factors</subject><issn>1757-6180</issn><issn>1757-6199</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEFPwyAUx4nRuGXu6NXwBVAYFOjRLOpMlkyjnhtKwaGjbYAm7tuPpbqbXN7j8Xv_hB8A1wTfMlIUd7Xr0AITgTCm5AxMiSgE4qQsz0-9xBMwj_EL50MXsmTlJZgsJCcC83IK0pvzwy6p1nRDhI1JJnjXquS6FnYWRvcD0z500bUGfueHaKBrt652qQsxt3A7eNXCfqeiV3DI3CdcvayX6BVtQqaC6qFXMcLYG51C500K-ytwYdUumvlvnYGPx4f35QqtN0_Py_s10pTRhKiwHBMpJeOMskIoWsuGN9xS1ghNhdGiKBvMbFHTmmtqDVNMNnlmeSEIoTOAxlydfxCDsVUfnFdhXxFcHQVWWWB1FFgdBWb-ZuT7ofamOdF_ujJQjoAd0hBM1M602lTjLW84nT39E34A_MOBbQ</recordid><startdate>20170601</startdate><enddate>20170601</enddate><creator>Ni, Mao-Wei</creator><creator>Zhou, Jie</creator><creator>Li, Hui</creator><creator>Chen, Wei</creator><creator>Mou, Han-Zhou</creator><creator>Zheng, Zhi-Guo</creator><general>Future Science Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20170601</creationdate><title>Simultaneous determination of six tyrosine kinase inhibitors in human plasma using HPLC-Q-Orbitrap mass spectrometry</title><author>Ni, Mao-Wei ; Zhou, Jie ; Li, Hui ; Chen, Wei ; Mou, Han-Zhou ; Zheng, Zhi-Guo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c343t-37f6018884643457a3b8d6d6f34d7c37ec759d04f5b3b6c3fe4a48d59df657113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Blood Chemical Analysis - methods</topic><topic>Chromatography, High Pressure Liquid - methods</topic><topic>Humans</topic><topic>Limit of Detection</topic><topic>Linear Models</topic><topic>method development</topic><topic>Protein Kinase Inhibitors - blood</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Protein-Tyrosine Kinases - antagonists & inhibitors</topic><topic>Q-Orbitrap</topic><topic>Tandem Mass Spectrometry - methods</topic><topic>therapeutic drug monitoring</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ni, Mao-Wei</creatorcontrib><creatorcontrib>Zhou, Jie</creatorcontrib><creatorcontrib>Li, Hui</creatorcontrib><creatorcontrib>Chen, Wei</creatorcontrib><creatorcontrib>Mou, Han-Zhou</creatorcontrib><creatorcontrib>Zheng, Zhi-Guo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Bioanalysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ni, Mao-Wei</au><au>Zhou, Jie</au><au>Li, Hui</au><au>Chen, Wei</au><au>Mou, Han-Zhou</au><au>Zheng, Zhi-Guo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Simultaneous determination of six tyrosine kinase inhibitors in human plasma using HPLC-Q-Orbitrap mass spectrometry</atitle><jtitle>Bioanalysis</jtitle><addtitle>Bioanalysis</addtitle><date>2017-06-01</date><risdate>2017</risdate><volume>9</volume><issue>12</issue><spage>925</spage><epage>935</epage><pages>925-935</pages><issn>1757-6180</issn><eissn>1757-6199</eissn><abstract>Gefitinib, erlotinib, icotinib, crizotinib, lapatinib and apatinib are targeted cancer therapy agents acting through inhibition of tyrosine kinase. Method for quantifying these six drugs in human plasma of patients was required.
An HPLC-Q-Orbitrap method (based on HPLC-MS/MS) was developed and validated for the simultaneous detection and quantitation of six tyrosine kinase inhibitors in human plasma. Sample was extracted by liquid-liquid extraction (ethyl acetate: tert-Butyl methyl ether, 1:1 v/v). The method shows a high level of accuracy and reproducibility. The lower limit of quantification was 0.02 ng/ml for apatinib, 0.1 ng/ml for crizotinib, 2.0 ng/ml for lapatinib and 0.05 ng/ml for erlotinib, gefitinib and icotinib. This method was successfully used for apatinib monitoring in plasma of patients with NSCLC.
This simple and reproducible method has potential for monitoring of tyrosine kinase inhibitors in patients' plasma.</abstract><cop>England</cop><pub>Future Science Ltd</pub><pmid>28617069</pmid><doi>10.4155/bio-2017-0031</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1757-6180 |
| ispartof | Bioanalysis, 2017-06, Vol.9 (12), p.925-935 |
| issn | 1757-6180 1757-6199 |
| language | eng |
| recordid | cdi_crossref_primary_10_4155_bio_2017_0031 |
| source | MEDLINE; PubMed Central |
| subjects | Blood Chemical Analysis - methods Chromatography, High Pressure Liquid - methods Humans Limit of Detection Linear Models method development Protein Kinase Inhibitors - blood Protein Kinase Inhibitors - pharmacology Protein-Tyrosine Kinases - antagonists & inhibitors Q-Orbitrap Tandem Mass Spectrometry - methods therapeutic drug monitoring Time Factors |
| title | Simultaneous determination of six tyrosine kinase inhibitors in human plasma using HPLC-Q-Orbitrap mass spectrometry |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T16%3A50%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Simultaneous%20determination%20of%20six%20tyrosine%20kinase%20inhibitors%20in%20human%20plasma%20using%20HPLC-Q-Orbitrap%20mass%20spectrometry&rft.jtitle=Bioanalysis&rft.au=Ni,%20Mao-Wei&rft.date=2017-06-01&rft.volume=9&rft.issue=12&rft.spage=925&rft.epage=935&rft.pages=925-935&rft.issn=1757-6180&rft.eissn=1757-6199&rft_id=info:doi/10.4155/bio-2017-0031&rft_dat=%3Cpubmed_cross%3E28617069%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/28617069&rfr_iscdi=true |